FDA Approves Carfilzomib and Daratumumab with Dexamethasone for Multiple Myeloma
The efficacy was evaluated in CANDOR and EQUULEUS trials
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1650 results
Talazoparib Does Not Prolong OS in BRCA1/2-mutated, HER2-negative Advanced Breast Cancer
Final overall survival results from the EMBRACA trial
Outcomes of Cancer Patients with SARS-CoV-2 Infection in Veneto
Findings from a large regional analysis of population that examined the prevalence of cancer and clinical outcomes of viral infection
Population Mortality from NSCLC in the US Fell Sharply Due to Treatment Advances
Evaluation of population level mortality trends attributed to specific subtypes of lung cancer
Combination of Azacitidine and Venetoclax in Previously Untreated AML
The findings from the VIALE-A study
Strict Safety Measures in Austria Results in Low SARS-CoV-2 Detection Rate in Cancer Patients
Findings from a large testing study conducted at a tertiary care hospital in Vienna
FDA Granted Accelerated Approval to Belantamab Mafodotin-blmf for Multiple Myeloma
It was evaluated in DREAMM-2 study
EMA Recommends Refusal of the Marketing Authorisation for Tagraxofusp
It was intended for the treatment of blastic plasmacytoid dendritic cell neoplasm
Potential Clinical Utility of ctDNA-based Surveillance in Patients Treated with ICI
The results of INSPIRE study
BRAF/MEK Inhibition May Be a Viable Treatment Strategy Across the Majority of BRAFV600 Mutated Cancers
Results of the NCI-MATCH Trial Subprotocol H
EMA Recommends Granting a Marketing Authorisation for Generic Arsenic Trioxide
Arsenic trioxide medac is a generic of Trisenox which has been authorised in the EU since 2002
FDA Grants Accelerated Approval to Tafasitamab-cxix for DLBCL
Efficacy of tafasitamab-cxix with lenalidomide was evaluated in L-MIND study